Genetic
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
Gene therapies represent a paradigm shift in medicine, with the potential to address the root causes of chronic diseases. They offer one-time treatment regimens and, in some cases, potentially a cure. As a result, they offer transformative value for patients, physicians, health systems and society. However, with the prospect of more gene therapy approvals there is concern in Europe that these technologies could threaten the financial sustainability of health systems.
The Promise of Gene Therapies: Are We Ready?
1 April 2021
In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In this interactive report we highlight our 5 key takeaways from the debate with clips, quotes and highlights.
Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The…
Genomics, Healthcare and Public Policy
1 October 1999
This Conference on Genomics, Healthcare and Public Policy, organised by the Office of Health Economics in collaboration with the School of Public Policy, University College London,…